Novo Nordisk (NVO) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Novo Nordisk, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track NVO live on Mooboard →

This week1

  • Oct 1, 2026
    Novo Nordisk(NVO)Phase 2/3 readout
    Ziltivekimab · Phase 3 · Heart Failure; Systemic Inflammation
    NCT06200207: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days1

  • Dec 14, 2026
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC0662-0419 · Phase 2 · Overweight; Obesity
    NCT07184632: A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity. Primary completion 2026-12-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later23

  • Jan 14, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    UBT251 · Phase 2 · Overweight; Obesity
    NCT07395687: A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity. Primary completion 2027-01-14 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 25, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Insulin icodec · Phase 3 · Diabetes Mellitus, Type 1
    NCT07076199: A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. Primary completion 2027-01-25 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 29, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Ziltivekimab · Phase 3 · Cardiovascular Risk; Acute Myocardial Infarction (AMI)
    NCT06118281: ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack. Primary completion 2027-01-29 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 1, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    CagriSema (Cagrilintide B and Semaglutide I) · Phase 3 · Obesity
    NCT07011667: A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Primary completion 2027-03-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 11, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Cagrilintide · Phase 3 · Obesity; Overweight
    NCT07220642: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide. Primary completion 2027-05-11 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 12, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Cagrilintide · Phase 3 · Overweight; Obesity
    NCT07220759: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide. Primary completion 2027-05-12 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 16, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    CDR132L · Phase 2 · Heart Failure
    NCT06979375: A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy. Primary completion 2027-05-16 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 18, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Cagrilintide · Phase 3 · Overweight; Obesity
    NCT07745504: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight. Primary completion 2027-05-18 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 9, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    CagriSema · Phase 3 · Diabetes Mellitus, Type 2
    NCT07817251: Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema. Primary completion 2027-06-09 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 14, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC0662-0419 · Phase 2 · Obesity
    NCT07639021: A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity. Primary completion 2027-06-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 27, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Etavopivat · Phase 3 · Sickle Cell Disease
    NCT06612268: A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease. Primary completion 2027-08-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 1, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Cagrilintide · Phase 3 · Cardiovascular Disease
    NCT05669755: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels. Primary completion 2027-09-01 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 3, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC0662-0419 · Phase 2 · Diabetes Mellitus, Type 2
    NCT07415954: A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes. Primary completion 2027-09-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 4, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    UBT251 · Phase 2 · Diabetes Mellitus, Type 2
    NCT07668388: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes. Primary completion 2027-10-04 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 7, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    Semaglutide · Phase 3 · Diabetes Mellitus, Type 2
    NCT03811561: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes. Primary completion 2027-11-07 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 16, 2027
    Novo Nordisk(NVO)Phase 2/3 readout
    CDR132L · Phase 2 · Heart Failure
    NCT06979362: A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy. Primary completion 2027-11-16 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 22, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    Semaglutide · Phase 3 · Overweight; Obesity
    NCT07770841: Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight. Primary completion 2028-02-22 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 23, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    Cagrisema · Phase 3 · Obesity; Type 2 Diabetes
    NCT07564414: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight. Primary completion 2028-02-23 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 29, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC6019-0001 · Phase 2 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
    NCT06260709: A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis. Primary completion 2028-02-29 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 6, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC0487-0111 · Phase 3 · Obesity
    NCT07503210: AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss. Primary completion 2028-06-06 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 26, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    NNC0487-0111 · Phase 3 · Obesity; Overweight
    NCT07571109: AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea. Primary completion 2028-06-26 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 27, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    zenagamtide · Phase 3 · Overweight; Obesity
    NCT07720271: AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight. Primary completion 2028-06-27 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2028
    Novo Nordisk(NVO)Phase 2/3 readout
    Mim8 · Phase 3 · Haemophilia A; Haemophilia A With Inhibitors
    NCT05685238: A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A. Primary completion 2028-06-30 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

How Novo Nordisk has moved — past-year price reactions

How binary is NVO? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.5%
typical day (1Y)
2
±10% days
46.5%
annualized vol
250
trading days
Largest single-day moves
  • -16.4%2026-02-23no matched headline
  • -14.6%2026-02-03no matched headline
  • +9.9%2026-02-06no matched headline
  • +9.1%2026-01-16no matched headline
  • -8.8%2026-07-31no matched headline
  • -8.2%2026-02-05no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Novo Nordisk — active clinical pipeline

Novo Nordisk's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

46 assets80 programsPh1 34Ph2 10Ph3 33· 3 post-marketing (Ph4)
AreasOncologyMetabolicCardiovascularRare / GeneticOther
NNC0487-0111Metabolic
Phase 1
Diabetes MellitusObesityOverweight (2)
Phase 3
Diabetes MellitusObesity (8)Overweight
CagrilintideMetabolic
Phase 1
Obesity (3)Overweight
Phase 3
Cardiovascular DiseaseObesity (3)Overweight (3)
SemaglutideMetabolic · GLP-1
Phase 3
Diabetes Mellitus, Type 2Non-alcoholic SteatohepatitisObesityOverweight
ConcizumabRare / Genetic · TFPI
Phase 3
Haemophilia A and B With and Without InhibitorsHaemophilia A With InhibitorsHaemophilia A Without Inhibitors
SomapacitanOther · GHR
Phase 2
Short Stature Children Born Small for Gestational Age (SGA)
Phase 3
SGASGA, Turner Syndrome, Noonan Syndrome, ISS
ZenagamtideMetabolic
Phase 3
ObesityOverweight (2)Type 2 Diabetes
ZiltivekimabCardiovascular · IL6
Phase 3
Cardiovascular RiskHeart FailureMyocardial Infarction
CagriSemaMetabolic
Phase 3
Diabetes Mellitus, Type 2Obesity
CagriSema (Cagrilintide B and Semaglutide I)Metabolic
Phase 3
Diabetes Mellitus, Type 2Obesity
DCR-PHXCOther · L-lactate dehydrogenase A chain mRNA
Phase 2
Primary Hyperoxaluria Type 1
Phase 3
Primary Hyperoxaluria Type 1 (PH1)
LiraglutideMetabolic · GLP-1
Phase 1
Obesity
Phase 3
Obesity
NNC6019-0001Rare / Genetic
Phase 2
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Phase 3
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DenecimigRare / Genetic
Phase 3
Haemophilia A
EtavopivatRare / Genetic · PKLR
Phase 3
Sickle Cell Disease
Etavopivat ARare / Genetic
Phase 3
Sickle Cell Disease
Insulin icodecMetabolic · INSR
Phase 3
Diabetes Mellitus, Type 1
Mim8Rare / Genetic
Phase 3
Haemophilia A
NNC0662-0419Metabolic
Phase 1
Overweight
Phase 2
Diabetes Mellitus, Type 2ObesityOverweight
UBT251Metabolic
Phase 1
ObesityOverweight
Phase 2
Diabetes Mellitus, Type 2Overweight
CDR132LCardiovascular
Phase 2
Heart Failure (2)
NNC0519-0130Other
Phase 2
Chronic Kidney Disease
NNC0537-1482Cardiovascular
Phase 1
Chronic Kidney DiseaseHeart Failure
Cagrilintide DMetabolic
Phase 1
Obesity
CagriSema (Cagrilintide B + semaglutide I)Metabolic
Phase 1
Obesity
CDR132L (i.v.)Cardiovascular
Phase 1
Heart Failure
CoramitugRare / Genetic
Phase 1
Transthyretin Amyloid Cardiomyopathy
DCR-PDL1Oncology
Phase 1
Solid Tumors, Adult
Glucose-dependent Insulinotropic Polypeptide (GIP)Metabolic
Phase 1
Overweight
INV-347Metabolic
Phase 1
Obesity
NNC0113-5840Metabolic
Phase 1
Obesity
NNC0194-0499Metabolic
Phase 1
Diabetes Mellitus, Type 1
NNC0442-0344 ARare / Genetic
Phase 1
Haemophilia A
NNC0497-0040Metabolic
Phase 1
Type 1 Diabetes (T1D)
NNC0581-0001Other
Phase 1
Hepatic Steatosis
NNC0638-0355Metabolic
Phase 1
Obesity
NNC0642-1895Other
Phase 1
Healthy volunteers
NNC0705-0002Other
Phase 1
Cardiometabolic Diseases
NNC0721-8060Metabolic
Phase 1
Overweight
NNC1679-0001Metabolic
Phase 1
Diabetes Mellitus, Type 2
NNC4004-0002Other
Phase 1
Hyperuricemia
NNC4005-001Metabolic
Phase 1
Fatty Liver Disease
NNC6022-0004Metabolic
Phase 1
Obesity
NNC6989-0001Metabolic
Phase 1
Overweight
NNC9733-0001Metabolic
Phase 1
Type 2 Diabetes
Zenagamtide injectionMetabolic
Phase 1
Overweight

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.